TY - JOUR T1 - Atorvastatin reduced major cardiovascular disease events in type 2 diabetes mellitus JF - Evidence Based Medicine JO - Evid Based Med SP - 43 LP - 43 DO - 10.1136/ebm.10.2.43 VL - 10 IS - 2 A2 - , Y1 - 2005/04/01 UR - http://ebm.bmj.com/content/10/2/43.abstract N2 - Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685–96.OpenUrlCrossRefPubMedWeb of Science 
 
 Q In patients with type 2 diabetes mellitus, is atorvastatin better than placebo for primary prevention of major cardiovascular disease (CVD) events? Clinical impact ratings GP/FP/Primary care ★★★★★★☆ IM/Ambulatory care ★★★★★★☆ Endocrine ★★★★★★☆ Cardiology ★★★★★★☆ Design: randomised placebo controlled trial (Collaborative Atorvastatin Diabetes Study [CARDS]). Allocation: concealed.* Blinding: blinded (clinicians, patients, pharmacists, data collectors, outcome assessors, monitoring committee, and data analysts).* Follow-up period: median 3.9 years. Setting: 132 clinical centres in the UK and Ireland. Patients: 2838 patients 40–75 years of age (mean age 62 y, 68% men) with type 2 diabetes mellitus (met 1985 World Health Organization criteria) who had ⩾1 of the following: a history of hypertension, retinopathy, microalbuminuria or macroalbuminuria, or a current smoking habit. Exclusion … ER -